Dendreon’s potential prostate cancer treatment Provenge gets May 1 FDA review date
By APFriday, November 20, 2009
Dendreon’s Provenge gets FDA review date
SEATTLE — Biotechnology company Dendreon Corp. said Friday the Food and Drug Administration will make a regulatory decision on the potential prostate cancer vaccine Provenge by May 1.
The drug is aimed at treating prostate cancer. It works as a vaccine to stimulate the body’s immune system so it fights the cancer, but is given as a treatment rather than a preventive.
Shares of Dendreon fell 4 cents to $28.01 in morning trading.
YOUR VIEW POINT
